Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Thalia Therap. (THAT) Share Price

Price 0.625p on 02-09-2026 at 18:25:12
Change -0.025p -3.85%
Buy 0.65p
Sell 0.60p
Last Trade: Sell 26,115.00 at 0.601p
Day's Volume: 434,713
Last Close: 0.625p
Open: 0.65p
ISIN: GB00BYW8QM32
Day's Range 0.625p - 0.65p
52wk Range: 0.425p - 0.90p
Market Capitalisation: £11.10m
VWAP: 0.601714p
Shares in Issue: 1.78b

Thalia Therap. (THAT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 26,115 0.601p Ordinary
12:42:17 - 02-Sep-26
Sell* 17,736 0.60p Ordinary
12:27:35 - 02-Sep-26
Buy* 4,000 0.65p SI Trade
08:29:51 - 02-Sep-26
Buy* 307 0.65p SI Trade
08:29:51 - 02-Sep-26
Buy* 153 0.65p SI Trade
08:29:51 - 02-Sep-26
Buy* 250 0.65p SI Trade
08:29:51 - 02-Sep-26
Buy* 307 0.65p SI Trade
08:29:51 - 02-Sep-26
Buy* 153 0.65p SI Trade
08:29:51 - 02-Sep-26
Sell* 40 0.60p SI Trade
08:29:51 - 02-Sep-26
Buy* 153 0.65p SI Trade
08:29:51 - 02-Sep-26
See more Thalia Therap. trades

Thalia Therap. (THAT) Share Price History

Time period:
to
Date Open High Low Close Volume
1st Sep 2026 (Tue) 0.65 0.65 0.65 0.65 2,031,397
31st Aug 2026 (Mon) 0.65 0.65 0.65 0.65 0
28th Aug 2026 (Fri) 0.65 0.65 0.65 0.65 788,379
27th Aug 2026 (Thu) 0.65 0.65 0.65 0.65 765,350
26th Aug 2026 (Wed) 0.65 0.65 0.65 0.65 29,312
25th Aug 2026 (Tue) 0.65 0.65 0.65 0.65 140,486
24th Aug 2026 (Mon) 0.65 0.65 0.65 0.65 168,213
21st Aug 2026 (Fri) 0.65 0.65 0.65 0.65 0
20th Aug 2026 (Thu) 0.65 0.65 0.65 0.65 124,734
19th Aug 2026 (Wed) 0.65 0.65 0.65 0.65 156,761
18th Aug 2026 (Tue) 0.65 0.65 0.65 0.65 1,418,835
17th Aug 2026 (Mon) 0.675 0.675 0.65 0.65 241,400
14th Aug 2026 (Fri) 0.675 0.675 0.675 0.675 436,898
13th Aug 2026 (Thu) 0.675 0.675 0.675 0.675 689
12th Aug 2026 (Wed) 0.675 0.675 0.675 0.675 285
11th Aug 2026 (Tue) 0.675 0.675 0.675 0.675 43,434
10th Aug 2026 (Mon) 0.675 0.675 0.675 0.675 194,105
7th Aug 2026 (Fri) 0.675 0.675 0.675 0.675 203,029
6th Aug 2026 (Thu) 0.675 0.675 0.675 0.675 81,799
5th Aug 2026 (Wed) 0.675 0.675 0.675 0.675 74,664
4th Aug 2026 (Tue) 0.675 0.675 0.675 0.675 202,941
3rd Aug 2026 (Mon) 0.675 0.675 0.675 0.675 238,579
See more Thalia Therap. price history

Thalia Therap. (THAT) Regulatory News

Date Source Headline
4th Aug 2026 10:30 am RNS Holding(s) in Company
31st Jul 2026 11:07 am RNS Total Voting Rights
29th Jul 2026 3:33 pm RNS Holding(s) in Company
23rd Jul 2026 9:25 am RNS Grant of Director Share Options
21st Jul 2026 5:23 pm RNS Holding(s) in Company
21st Jul 2026 5:21 pm RNS Holding(s) in Company
21st Jul 2026 11:36 am RNS Holding(s) in Company
17th Jul 2026 11:21 am RNS Result of AGM and Completion of Acquisition
17th Jul 2026 7:00 am RNS AGM Statement
24th Jun 2026 3:21 pm RNS Posting of Annual Report and Notice of AGM
See more Thalia Therap. regulatory news

Thalia Therap. (THAT) Share News

UK shareholder meetings calendar - next 7 days

10th Jul 2026 13:43

Read More

TRADING UPDATES: Tullow Oil makes partial notes repayment

24th Jun 2026 13:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

LONDON MARKET MIDDAY: Stocks mixed but no "contagion" from US sell-off

24th Jun 2026 11:59

(Alliance News) - The FTSE 100 was higher at midday on Wednesday, boosted by Segro after it rejected an "opportunistically timed" takeover proposal, and as the US and Iran reportedly prepare to restart 'technical talks'. Read More

IN BRIEF: Thalia Therapeutics eyes adding microRNA therapeutic asset

23rd Jun 2026 20:20

Thalia Therapeutics PLC - biotechnology company developing innovative RNA therapeutics - Pretax loss is flat at GBP1.2 million in 2025 when compared to the year prior. Loss per share is 0.17 pence versus 0.31p the year before, revenue is little changed at GBP7,264 versus GBP7,282. Research and development costs fall to GBP214,120 from GBP390,387 and general and administration costs rise to GBP1.0 million from GBP837,996. "Alongside our internally developed assets, we are in advanced stages of potentially adding a clinical-stage microRNA therapeutic asset to the company's portfolio. If successful, this, combined with the continued advancement of Nuvec, our dual-targeting siRNA programme, is the first step in creating a differentiated and valuable RNA therapeutics company," says Chief Executive David Solomon. Read More

EARNINGS AND TRADING: Asia Strategic Holdings revenue declines

9th Jun 2026 18:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

See more Thalia Therap. news
FTSE 100 Latest
Value10,756.45
Change-32.83

Login to your account

Forgot Password?

Not Registered